Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Germain

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
The International Journal on Drug Policy|January 29, 2021
Service provision and barriers to care for men who have sex with men engaging in chemsex and sexualised drug use in EnglandMatthew Peter Hibbert, Jennifer S Germain, Caroline E Brett, et al.
Cancer Research|April 3, 2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitroPeter J Houghton, Glen S Germain, Franklin C Harwood, et al.
The Journal of Biological Chemistry|February 16, 2002
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycinMichael B Dilling, Glen S Germain, Lorina Dudkin, et al.
Molecular Pharmacology|May 1, 1994
Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)ureaJ Sosinski, J H Thakar, G S Germain, et al.
Cancer Research|January 25, 2003
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathwaysKuntebommanahalli N Thimmaiah, John Easton, Shile Huang, et al.
Cancer Research|September 15, 1990
Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell lineD N Shapiro, P J Houghton, B J Hazelton, et al.
Journal of Dental Research|September 18, 2024
Multiscale Imaging to Monitor Functional SHED-Supported Engineered VesselsE Chatzopoulou, N Bousaidi, T Guilbert, et al.
The Journal of Biological Chemistry|July 13, 2005
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signalingKuntebommanahalli N Thimmaiah, John B Easton, Glen S Germain, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary resultsS Dollfus, S Germain-Robin, B Chabot, et al.
Molecular Pharmacology|January 13, 1998
Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoproteinJ K Horton, K N Thimmaiah, G A Altenberg, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
The International Journal on Drug Policy|January 29, 2021
Service provision and barriers to care for men who have sex with men engaging in chemsex and sexualised drug use in EnglandMatthew Peter Hibbert, Jennifer S Germain, Caroline E Brett, et al.
Cancer Research|April 3, 2004
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitroPeter J Houghton, Glen S Germain, Franklin C Harwood, et al.
The Journal of Biological Chemistry|February 16, 2002
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycinMichael B Dilling, Glen S Germain, Lorina Dudkin, et al.
Molecular Pharmacology|May 1, 1994
Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)ureaJ Sosinski, J H Thakar, G S Germain, et al.
Cancer Research|January 25, 2003
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathwaysKuntebommanahalli N Thimmaiah, John Easton, Shile Huang, et al.
Cancer Research|September 15, 1990
Morphological and molecular characterization of spontaneous myogenic differentiation in a human rhabdomyosarcoma cell lineD N Shapiro, P J Houghton, B J Hazelton, et al.
Journal of Dental Research|September 18, 2024
Multiscale Imaging to Monitor Functional SHED-Supported Engineered VesselsE Chatzopoulou, N Bousaidi, T Guilbert, et al.
The Journal of Biological Chemistry|July 13, 2005
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signalingKuntebommanahalli N Thimmaiah, John B Easton, Glen S Germain, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|August 25, 2009
Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary resultsS Dollfus, S Germain-Robin, B Chabot, et al.
Molecular Pharmacology|January 13, 1998
Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoproteinJ K Horton, K N Thimmaiah, G A Altenberg, et al.
Pageof 9